Telix publishes investor presentation outlining radiopharmaceutical growth strategy and pipeline updates

Telix

Telix

TLX

0.00
  • Telix outlined 16% quarter-on-quarter growth in Q1 2026 Precision Medicine sales to USD 186 million.
  • Two FDA-cleared PSMA imaging agents now marketed across 22 countries; China NDA under NMPA review; Japan registration-enabling study underway.
  • Glioma imaging agent Pixclara/Pixlumi flagged with a Sep. 11, 2026 PDUFA date; European MAA accepted.
  • Renal mass imaging program advanced through two FDA Type A meetings; BLA resubmission in progress.
  • Pipeline focus includes TLX591-Tx Phase 3 in PSMA+ mCRPC and TLX101-Tx pivotal recurrent GBM study; Precision Medicine growth framed at 20%-40% CAGR.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telix Pharmaceuticals Ltd. published the original content used to generate this news brief on June 01, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.